CCI approves merger of nine pharma entities with Sequent Scientific
New Delhi: The Competition Commission of India has approved the proposed amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with Sequent Scientific Limited.
Sequent Scientific Limited is a publicly listed company, having operations globally in the animal healthcare industry. The company offers a comprehensive range of Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDFs), and analytical services to meet the needs of the animal health sector. Sequent Research Limited (SRL) is a wholly owned subsidiary of SSL, which operates as a Contract Research Organization providing analytical services and a wide array of testing to the global pharmaceutical industry.
The Proposed Combination involves a series of inter-connected steps carried out for the amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with SSL as the ultimate surviving entity (Proposed Combination).
Read also: Roquette seeks CCI nod for IFF Pharma solutions biz acquisition
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.